CD163 and breast cancer: Although studies reported poor prognosis in patients with CD163- expressing cells in breast cancer (Shabo et al., 2008) and rectal cancer (Shabo et al., 2009); another study reported favorable clinicopathological features in colon cancer (Koelzer et al., 2015).